| Literature DB >> 24098394 |
Jian Chen1, Mingyan Lin, John J Foxe, Erika Pedrosa, Anastasia Hrabovsky, Reed Carroll, Deyou Zheng, Herbert M Lachman.
Abstract
Induced pluripotent stem cell (iPSC) technology is providing an opportunity to study neuropsychiatric disorders through the capacity to grow patient-specific neurons in vitro. Skin fibroblasts obtained by biopsy have been the most reliable source of cells for reprogramming. However, using other somatic cells obtained by less invasive means would be ideal, especially in children with autism spectrum disorders (ASD) and other neurodevelopmental conditions. In addition to fibroblasts, iPSCs have been developed from cord blood, lymphocytes, hair keratinocytes, and dental pulp from deciduous teeth. Of these, dental pulp would be a good source for neurodevelopmental disorders in children because obtaining material is non-invasive. We investigated its suitability for disease modeling by carrying out gene expression profiling, using RNA-seq, on differentiated neurons derived from iPSCs made from dental pulp extracted from deciduous teeth (T-iPSCs) and fibroblasts (F-iPSCs). This is the first RNA-seq analysis comparing gene expression profiles in neurons derived from iPSCs made from different somatic cells. For the most part, gene expression profiles were quite similar with only 329 genes showing differential expression at a nominally significant p-value (p<0.05), of which 63 remained significant after correcting for genome-wide analysis (FDR <0.05). The most striking difference was the lower level of expression detected for numerous members of the all four HOX gene families in neurons derived from T-iPSCs. In addition, an increased level of expression was seen for several transcription factors expressed in the developing forebrain (FOXP2, OTX1, and LHX2, for example). Overall, pathway analysis revealed that differentially expressed genes that showed higher levels of expression in neurons derived from T-iPSCs were enriched for genes implicated in schizophrenia (SZ). The findings suggest that neurons derived from T-iPSCs are suitable for disease-modeling neuropsychiatric disorder and may have some advantages over those derived from F-iPSCs.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24098394 PMCID: PMC3789755 DOI: 10.1371/journal.pone.0075682
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1immunostaining for GAD, TH, βIII-tubulin and VGLUT2 in TIPS4 neurons (day 14), and PSD95 and synaptophysin (SYN) in day 56 neurons.
Lower right: Train of action potentials with and without tetrodoxin (TTX) in day 35 neurons.
Top differentially expressed genes (fold change; FC) that decrease during differentiation into NPCs.
| Gene | FPKM iPSCs | FPKM NPCs | FPKM iPSCs | FPKM NPCs | log2 FC | p-value | FDR |
| TIPS4 | TIPS4 | TIPS4-C5 | TIPS4-C5 | NPCs/iPSCs | |||
| RP11-256I9.2 | 2100.54 | 0.00 | 126.91 | 0.00 | −17.77 | 9.31E-39 | 1.49E-35 |
| RP11-132A1.3 | 42.89 | 0.00 | 39.36 | 0.00 | −13.01 | 1.42E-24 | 6.59E-22 |
| ESRG | 439.88 | 0.08 | 374.93 | 0.03 | −12.82 | 2.71E-56 | 9.76E-53 |
| RP11-1144P22.1 | 192.17 | 0.05 | 126.90 | 0.00 | −12.43 | 1.51E-38 | 1.97E-35 |
| RP11-277P12.10 | 39.44 | 0.00 | 13.94 | 0.00 | −12.38 | 1.71E-08 | 9.11E-07 |
| PRDM14 | 22.11 | 0.00 | 19.11 | 0.00 | −12.01 | 3.22E-31 | 2.32E-28 |
| CTD-2142D14.1 | 21.65 | 0.00 | 15.39 | 0.00 | −11.86 | 1.60E-11 | 1.57E-09 |
| TRIML2 | 13.32 | 0.00 | 19.97 | 0.00 | −11.70 | 6.21E-11 | 5.54E-09 |
| FOXH1 | 81.94 | 0.03 | 34.75 | 0.00 | −11.70 | 1.91E-31 | 1.44E-28 |
| CTD-2501M5.1 | 20.49 | 0.00 | 11.22 | 0.00 | −11.63 | 1.02E-13 | 1.47E-11 |
| LINC00678 | 184.49 | 0.05 | 111.91 | 0.04 | −11.60 | 3.09E-37 | 3.71E-34 |
| TDGF1 | 541.72 | 0.31 | 422.70 | 0.03 | −11.43 | 4.40E-50 | 1.27E-46 |
| VRTN | 41.60 | 0.01 | 29.62 | 0.01 | −11.33 | 1.65E-39 | 2.97E-36 |
| RP1-46F2.2 | 11.17 | 0.00 | 9.79 | 0.00 | −11.03 | 2.64E-04 | 4.55E-03 |
| DPEP3 | 9.15 | 0.00 | 8.92 | 0.00 | −10.82 | 2.46E-17 | 5.62E-15 |
| ZFP42 | 87.65 | 0.07 | 56.90 | 0.00 | −10.81 | 1.32E-38 | 1.90E-35 |
| RP11-469A15.2 | 10.63 | 0.00 | 7.11 | 0.00 | −10.79 | 6.98E-06 | 2.00E-04 |
| CTD-2306M5.1 | 8.55 | 0.00 | 7.92 | 0.00 | −10.69 | 3.14E-06 | 9.98E-05 |
| DAZL | 8.51 | 0.00 | 7.19 | 0.00 | −10.62 | 2.17E-12 | 2.58E-10 |
| CCL26 | 6.35 | 0.00 | 8.76 | 0.00 | −10.56 | 5.17E-05 | 1.16E-03 |
Largest fold change (FC) increase in gene expression during transition from iPSCs to NPCs.
| gene | FPKM TIPS4iPSCs | FPKM TIPS4NPCs | FPKM TIPS4-C5iPSCs | FPKM TIPS4-C5NPCs | log2 FC | p-value | FDR |
| HOXA2 | 0 | 10.76 | 0 | 37.47 | 12.24 | 8.37E-05 | 1.73E-03 |
| RP11-649A16.1 | 0 | 20.33 | 0 | 2.90 | 11.18 | 9.35E-04 | 1.33E-02 |
| DCN | 0.12 | 249.16 | 0 | 21.72 | 11.01 | 1.57E-03 | 2.05E-02 |
| HOXA-AS2 | 0.00 | 15.01 | 0 | 2.03 | 10.74 | 5.61E-04 | 8.66E-03 |
| HOXA3 | 0.00 | 10.53 | 0 | 5.14 | 10.61 | 1.33E-11 | 1.33E-09 |
| NPR3 | 0.04 | 60.66 | 0 | 10.38 | 10.46 | 2.96E-03 | 3.42E-02 |
| RGCC | 0.00 | 2.37 | 0 | 8.93 | 10.14 | 4.39E-05 | 1.02E-03 |
| PRRX1 | 0.22 | 244.97 | 0.04 | 39.91 | 10.02 | 2.51E-03 | 2.99E-02 |
| DLX1 | 0.02 | 27.60 | 0.01 | 14.65 | 10.00 | 6.28E-12 | 6.59E-10 |
| AC018730.3 | 0.00 | 2.73 | 0.00 | 7.11 | 9.94 | 6.59E-05 | 1.42E-03 |
| NTRK2 | 0.01 | 8.74 | 0.04 | 41.85 | 9.86 | 1.83E-03 | 2.32E-02 |
| RP11-266O8.1 | 0.00 | 3.71 | 0.00 | 5.45 | 9.84 | 1.70E-03 | 2.18E-02 |
| PALMD | 0.00 | 7.41 | 0.00 | 1.34 | 9.77 | 5.47E-04 | 8.45E-03 |
| MKRN3 | 0.00 | 3.80 | 0.00 | 4.88 | 9.76 | 1.01E-08 | 5.77E-07 |
| LUM | 0.17 | 105.17 | 0.00 | 51.55 | 9.75 | 1.61E-07 | 7.08E-06 |
| ABCC9 | 0.00 | 5.38 | 0.00 | 2.67 | 9.65 | 1.38E-08 | 7.50E-07 |
| NR2F1 | 0.09 | 28.86 | 0.07 | 105.66 | 9.64 | 4.07E-08 | 2.00E-06 |
| POU3F3 | 0.03 | 15.55 | 0.02 | 28.40 | 9.63 | 5.24E-22 | 2.04E-19 |
| RP11-73C9.1 | 0.00 | 4.25 | 0.00 | 3.63 | 9.62 | 4.12E-03 | 4.49E-02 |
| PDZRN4 | 0.00 | 15.07 | 0.01 | 1.02 | 9.57 | 3.97E-04 | 6.50E-03 |
Largest fold change (FC) increase in gene expression during transition from iPSCs to Neurons.
| Gene | FPKM TIPS4iPSCs | FPKM TIPS4neurons | FPKM TIPS4-C5iPSCs | FPKM TIPS4-C5neurons | log2 FC | p-value | FDR |
| LINC00473 | 0.00 | 40.37 | 0.00 | 12.46 | 12.37 | 2.95E-04 | 3.63E-03 |
| SST | 0.00 | 9.25 | 0.00 | 41.43 | 12.31 | 7.79E-03 | 4.53E-02 |
| HOXA2 | 0.00 | 4.92 | 0.00 | 39.53 | 12.12 | 7.33E-05 | 1.16E-03 |
| NEUROD6 | 0.00 | 27.12 | 0.00 | 6.10 | 11.70 | 1.47E-03 | 1.31E-02 |
| NPR3 | 0.04 | 137.91 | 0.00 | 8.34 | 11.50 | 1.51E-03 | 1.35E-02 |
| GS1-211B7.1 | 0.00 | 5.47 | 0.00 | 16.53 | 11.10 | 6.34E-03 | 3.89E-02 |
| ABCA8 | 0.00 | 6.59 | 0.00 | 15.15 | 11.09 | 8.06E-06 | 1.75E-04 |
| DIO3 | 0.00 | 12.12 | 0.00 | 9.16 | 11.06 | 3.38E-21 | 1.11E-18 |
| IFI44 | 0.00 | 18.62 | 0.00 | 2.07 | 11.02 | 8.08E-03 | 4.67E-02 |
| HOXB2 | 0.00 | 2.80 | 0.02 | 52.66 | 10.84 | 5.33E-03 | 3.44E-02 |
| GRIA2 | 0.05 | 31.86 | 0.00 | 72.12 | 10.81 | 6.60E-07 | 2.00E-05 |
| NTRK2 | 0.01 | 11.19 | 0.04 | 85.39 | 10.80 | 8.15E-04 | 8.16E-03 |
| HOXA3 | 0.00 | 5.19 | 0.00 | 10.41 | 10.61 | 7.58E-12 | 6.73E-10 |
| RP11-649A16.1 | 0.00 | 5.99 | 0.00 | 8.93 | 10.54 | 1.50E-03 | 1.34E-02 |
| ZFHX4-AS1 | 0.00 | 17.75 | 0.03 | 32.91 | 10.47 | 7.66E-12 | 6.76E-10 |
| HOXB7 | 0.00 | 2.97 | 0.00 | 9.88 | 10.33 | 3.34E-04 | 4.05E-03 |
| STMN4 | 0.03 | 75.48 | 0.10 | 105.04 | 10.32 | 2.70E-23 | 1.25E-20 |
| HOXB3 | 0.00 | 2.40 | 0.02 | 31.80 | 10.24 | 1.35E-03 | 1.23E-02 |
| NR2F1 | 0.09 | 73.09 | 0.07 | 130.71 | 10.24 | 6.27E-09 | 3.11E-07 |
| PDZRN4 | 0.00 | 5.58 | 0.01 | 19.20 | 10.19 | 1.77E-04 | 2.41E-03 |
Pathway Analysis for genes that increase in neurons.
| Category | FunctionsAnnotation | p-Value | # Molecules |
| Cancer | adenocarcinoma | 4.20E-12 | 427 |
| Cancer | lung adenocarcinoma | 4.54E-12 | 359 |
| Respiratory Disease | lung adenocarcinoma | 4.54E-12 | 359 |
| Hereditary Disorder | Schizophrenia | 8.47E-12 | 85 |
| Neurological Disease | Schizophrenia | 8.47E-12 | 85 |
| Psychological Disorders | Schizophrenia | 8.47E-12 | 85 |
| Cancer | carcinoma in lung | 8.21E-11 | 372 |
| Respiratory Disease | carcinoma in lung | 8.21E-11 | 372 |
| Cancer | lung tumor | 5.61E-10 | 377 |
| Respiratory Disease | lung tumor | 5.61E-10 | 377 |
| Cancer | lung cancer | 5.82E-10 | 375 |
| Respiratory Disease | lung cancer | 5.82E-10 | 375 |
Pathway Analysis for genes that decrease in neurons.
| Category | Functions Annotation | p-Value | # Molecules |
| Cancer | uterine serous papillary cancer | 1.78E-16 | 59 |
| Reproductive System Disease | uterine serous papillary cancer | 1.78E-16 | 59 |
| Cell Cycle | G2 phase | 2.97E-11 | 40 |
| DNA Replication, Recombination, Repair | metabolism of DNA | 4.45E-11 | 49 |
| Cell Cycle | cell cycle progression | 1.25E-10 | 100 |
| DNA Replication, Recombination, Repair | DNA replication | 1.39E-10 | 34 |
| Cell Cycle | G2/M phase | 1.53E-10 | 33 |
| Cell Cycle | segregation of chromosomes | 2.35E-10 | 22 |
| DNA Replication, Recombination, Repair | segregation of chromosomes | 2.35E-10 | 22 |
| Cellular Assembly and Organization | segregation of chromosomes | 2.35E-10 | 22 |
| Cancer | endometrial cancer | 2.50E-10 | 65 |
| Reproductive System Disease | endometrial cancer | 2.50E-10 | 65 |
| Cell Cycle | mitosis of tumor cell lines | 3.59E-10 | 26 |
| Cancer | colon tumor | 5.19E-10 | 102 |
| Gastrointestinal Disease | colon tumor | 5.19E-10 | 102 |
| DNA Replication, Recombination, Repair | alignment of chromosomes | 5.70E-10 | 12 |
| Cellular Assembly and Organization | alignment of chromosomes | 5.70E-10 | 12 |
| Cancer | mammary tumor | 5.88E-10 | 144 |
| Cell Cycle | arrest in mitosis | 7.76E-10 | 16 |
Figure 2Differential expression between T-iPSCs and F-iPSCs (mean log2 fold change) for all HOX genes expressed at FPKM >1.
Asterisk denotes FDR<0.05.
Pathway analysis for differentially expressed genes (uncorrected) T-iPSC neurons vs F-iPSC neurons.
| Category | Functions Annotation | p-Value | Molecules (increased in T-IPSC neurons) |
| Neurological Disease | Schizophrenia | 3.24E-04 | ATP1A2, CELF2, CHL1, CLDN5, CNTNAP2, DAB1, FOXP2, GRM3, NELL2, NTF3, SCD5, TAC1, TTR |
| Neurological Disease | malformation of brain | 3.94E-04 | ARX, CNTNAP2, EOMES, MEF2C, VLDLR |
| Neurological Disease | type 1 lissencephaly | 9.70E-04 | ARX, VLDLR |
| Neurological Disease | seizure disorder | 2.04E-03 | ARX, ATP1A2, CNTNAP2, GPR98, KCNQ3, MEF2C, PRICKLE1, TAC1 |
| Neurological Disease | speech and language disorders | 3.45E-03 | ARX, FOXP1, FOXP2 |
| Neurological Disease | epilepsy | 4.12E-03 | ARX, ATP1A2, CNTNAP2, KCNQ3, MEF2C, PRICKLE1, TAC1 |
|
|
|
|
|
| Cellular Development | differentiation of tumor cell lines | 1.29E-06 | ASCL1, BTG2, CCND1, DLK1, HOXA5, JAG1, KLF4, NOTCH1, NTRK2, PRKCD, PRKD3, WNT7A, ZBTB16 |
| Cellular Growth andProliferation | proliferation of epithelial cells | 1.14E-05 | CCND1, ITGB8, NOTCH1, PAX2, PRKCD, PTPRZ1, RGS4, VIP, WNT7A |
| Cellular Development | differentiation of cells | 1.40E-05 | ASCL1, BTG2, CCND1, DLK1, DLL1, FRZB, HOXA5, HOXA7, HOXA9, HS6ST1, JAG1, KLF4, MAL, NOTCH1, NTRK2, PRKCD, PRKD3, PTCH1, RGS4, TESC, WNT7A, ZBTB16 |
| Psychological Disorders | Anxiety Disorders | 1.84E-05 | ADRA1A, CA14, CACNA2D3, GABRR1, GAD2, OPRM1, SLC32A1, SLC6A1 |
| Neurological Disease | seizures | 2.44E-05 | ANKRD6, CA14, CACNA2D3, CYYR1, GABRR1, GAD1, GAD2, KLF10, LAMP5, PCSK1, SLC32A1, SLC6A1 |